BMS 963272
Alternative Names: BMS-963272Latest Information Update: 28 Mar 2024
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Non-alcoholic fatty liver disease
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in USA
- 28 Nov 2021 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in USA (PO, Capsule)
- 12 Aug 2021 Bristol-Myers Squibb terminates a phase I clinical trial in Non-alcoholic fatty liver disease in USA, due to change in business objectives (NCT04766476)